AstraZeneca spinoff Viela has raised nearly $390m in funding and has filed for an initial public offering that would also allow 6 Dimensions Capital to exit.

Viela Bio, the US-based autoimmune disease therapy developer spun off by pharmaceutical firm AstraZeneca, has filed to raise up to $150m in an initial public offering. Spun off in 2018, Viela is working on drugs to treat autoimmune diseases and severe inflammatory diseases. Its therapies will target the disorders’ molecular pathogenesis in order to more…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.